NCT00310713

Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine

A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the C Saccharide Component of Chiron's Meningococcal C Conjugate Vaccine Administered to Healthy Children at Least 12 Months of Age After Priming With a Commercially Available Men ACWY Conjugate Vaccine at 2, 3 and 4 Months of Age

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 33 (actual)
• Sponsor: Novartis Vaccines · Industry
• Sex: All
• Age: 12 Months – 13 Months
• Healthy volunteers: Accepted

Summary

Persistence of antibodies and kinetics of B cell response in healthy children after vaccination with MCC vaccine

Conditions

• Prevention of Meningococcal Infection

Interventions

Type	Name	Description
BIOLOGICAL	Meningococcal C conjugate vaccine	Group 1: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 3 post immunization) Group 2: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 5 post immunization) Group 3: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 7 post immunization) Group 4: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 9 post immunization) Group 5: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 10 post immunization)

Timeline

• Start date: 2006-04-01
• Primary completion: 2006-08-01
• Completion: 2006-08-01
• First posted: 2006-04-04
• Last updated: 2014-09-19

Locations

1 site across 1 country: United Kingdom